Sam Brusco, Associate Editor03.08.21
Second Sight Medical Products, a maker of implantable visual prosthetics that create an artificial form of useful vision for blind individuals, received U.S. Food and Drug Administration (FDA) approval the Argus 2s Retinal Prosthesis System, a redesigned set of external hardware (glasses and video processing unit) initially used in combination with previously implanted Argus II systems to treat retinitis pigmentosa. The company expects to adapt Argus 2s as the external system for the next-gen Orion Visual Cortical Prosthesis System under development.
Argus 2 also touts more processing power, potentially allowing improved video processing.
“We are very pleased to have received this approval, as it presents an opportunity to offer external hardware that we believe enhance comfort and aesthetics compared with the legacy Argus II system,” Matthew Pfeffer, acting Second Sight CEO told the press.
Decision about when (or if) to begin production of Argus 2s is pending completion of Second Sight’s currently in progress planned business combination with Pixium Vision. Should it be completed, the new management team will assess how best to proceed with the Argus 2s and all other products in development.
Argus 2 also touts more processing power, potentially allowing improved video processing.
“We are very pleased to have received this approval, as it presents an opportunity to offer external hardware that we believe enhance comfort and aesthetics compared with the legacy Argus II system,” Matthew Pfeffer, acting Second Sight CEO told the press.
Decision about when (or if) to begin production of Argus 2s is pending completion of Second Sight’s currently in progress planned business combination with Pixium Vision. Should it be completed, the new management team will assess how best to proceed with the Argus 2s and all other products in development.
